Retrophin Inc. Daily Stock Analysis

Daily Stock Analysis, RTRX, Retrophin Inc, priceseries

Retrophin Inc. Daily Stock Analysis
Stock Information
Open
25.50
Close
24.66
High
25.50
Low
23.75
Previous Close
24.25
Daily Price Gain
0.41
YTD High
37.04
YTD High Date
Aug 5, 2015
YTD Low
0.90
YTD Low Date
Nov 7, 2011
YTD Price Change
23.76
YTD Gain
2640.00%
52 Week High
37.04
52 Week High Date
Aug 5, 2015
52 Week Low
0.90
52 Week Low Date
Nov 7, 2011
52 Week Price Change
23.76
52 Week Gain
2640.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 16. 2017
18.10
Jun 27. 2017
19.12
7 Trading Days
5.65%
Link
LONG
Aug 11. 2017
21.83
Sep 8. 2017
24.14
19 Trading Days
10.59%
Link
LONG
Feb 27. 2018
23.78
Mar 13. 2018
25.23
10 Trading Days
6.10%
Link
LONG
Apr 6. 2018
23.48
Apr 30. 2018
26.18
16 Trading Days
11.51%
Link
LONG
May 11. 2018
26.32
May 31. 2018
28.16
13 Trading Days
7.01%
Link
LONG
Aug 16. 2018
27.05
Sep 5. 2018
28.89
13 Trading Days
6.79%
Link
LONG
Mar 24. 2020
11.96
Apr 15. 2020
14.92
15 Trading Days
24.79%
Link
Company Information
Stock Symbol
RTRX
Exchange
NasdaqGM
Company URL
http://www.retrophin.com
Company Phone
760-260-8600
CEO
Stephen J. Aselage
Headquarters
California
Business Address
3721 VALLEY CENTRE DR., SUITE 200, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001438533
About

Retrophin, Inc. operates as a biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It focuses on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Description

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading